influenza vaccine

Overview

The influenza vaccine elicits protective immunity against influenza virus, chiefly by generating antibodies against the surface glycoprotein hemagglutinin (HA), which the virus uses to bind host cells; neuraminidase contributes as a secondary target. Formulations differ by population and platform: standard-dose inactivated vaccines, high-dose or adjuvanted versions for older adults whose responses are weaker, live-attenuated vaccine given intranasally, and recombinant protein vaccines produced without eggs. Children aged 6–35 months receive a reduced dose (0.25 mL, 7.5 μg HA per strain) while older children and adults receive the full amount.

Annual reformulation is forced by the virus rather than chosen. Point mutations accumulate in the antibody-binding sites of HA — antigenic drift — so last season's antibodies bind this season's virus less well, and strain selection must be made months ahead of the season, with mismatch a recurring cause of low effectiveness. Effectiveness is therefore variable, typically moderate and lower in years of poor match or in older adults, and egg-based manufacture adds its own problem, since adaptation of the seed virus to grow in eggs can itself alter the antigenic surface. Reassortment between influenza A viruses of different hosts — antigenic shift — produces the abrupt novel subtypes behind pandemics, against which seasonal vaccines offer little.

Vaccination matters most for those least able to withstand infection: older adults, young infants, pregnant women, and immunocompromised people, including those on immunosuppressive Targeted therapies such as rituximab, which depletes the B cells the vaccine depends on. Patients receiving immune checkpoint inhibitors are also a group of interest, though these agents enhance rather than suppress immune responses. No vaccine is approved below six months of age, leaving maternal immunization as the means of protecting the youngest infants. That gap, together with the yearly reformulation cycle and the short duration of protection, motivates work toward universal vaccines — HA stem-targeting nanoparticle designs and adjuvanted platforms aimed at the conserved regions that drift cannot easily change.

Recent Publications Summary

Recent publications on influenza vaccine focused on both real-world effectiveness and implementation barriers across diverse populations. Several studies estimated vaccine effectiveness against influenza-associated outcomes in children and adolescents, including primary care visits, outpatient visits, and hospitalization across multiple seasons in Europe and elsewhere, with one study also examining the impact of repeated annual vaccination on protection against influenza-associated hospitalization 41936398Apr41936402Apr41589063Jan. Another nationwide retrospective cohort study in Brazil evaluated hospitalized laboratory-confirmed influenza cases and found that COVID-19 booster vaccination was independently associated with reduced mortality, while also reporting that influenza A predominated and was associated with higher mortality than influenza B 42324378Jun.

Other publications addressed vaccine acceptance, hesitancy, and delivery. Among pediatric healthcare workers, social media use was associated with influenza vaccine hesitancy, with confidence, complacency, and convenience acting as mediating factors in the relationship 42127305May. A cross-sectional survey in seven Chinese megacities examined the prevalence and determinants of influenza vaccine hesitancy in urban populations 42071229May. In healthcare workers, a discrete choice experiment assessed how enhanced influenza vaccines might affect vaccination uptake and projected coverage in Hong Kong 41921480Apr. A national pediatric inpatient study also examined how the COVID-19 pandemic affected delivery of inpatient vaccines, including influenza vaccines 42128415May.

safety and policy-oriented studies further broadened the evidence base. In Canadian children and adolescents with autoimmune and/or immunocompromised conditions, active surveillance was used to evaluate post-vaccination health events after seasonal influenza vaccination, either alone or co-administered with COVID-19 vaccine 42053343Apr. In India, investigators estimated the burden of influenza and the cost-effectiveness and budgetary impact of introducing a publicly funded seasonal influenza vaccination programme for adults aged 60 years and older 42062199Apr. Together, these studies highlight ongoing efforts to quantify influenza vaccine effectiveness, understand hesitancy and uptake, assess safety in vulnerable groups, and inform vaccination policy and delivery strategies 41936398Apr41936402Apr41589063Jan42127305May42071229May41921480Apr42053343Apr42062199Apr42128415May.

What Changes, What Holds

1. Vaccine performance remains season- and outcome-dependent, with repeated annual dosing still an open question for hospitalization protection
REINFORCES These studies sharpen the baseline claim that seasonal influenza vaccination is a moving target because circulating strains and timing matter. They also extend effectiveness evidence into real-world pediatric and adolescent outcomes across settings, while leaving the core account intact. The repeated-vaccination finding does not overturn the established role of annual vaccination; it instead suggests that durability and cumulative benefit against severe outcomes may vary by season and prior exposure. 41936398Apr41936402Apr

2. Influenza vaccine delivery is constrained by hesitancy and implementation barriers rather than by immunologic limits alone
NEW DIRECTION This work adds a behavioral and systems-level dimension that the Overview does not cover: uptake depends on confidence, complacency, convenience, and context, not just vaccine availability or formulation. It also suggests that enhanced products may change acceptance, which matters for public health use even if immunogenicity is unchanged. The pandemic-related inpatient delivery findings further indicate that access pathways can be disrupted independently of vaccine science. 42127305May41921480Apr

3. safety and policy decisions now need to account for coadministration, vulnerable hosts, and cost-effectiveness, not just vaccine composition
NEW DIRECTION These studies broaden the baseline by addressing post-vaccination health events in children and adolescents with autoimmune or immunocompromised conditions, including when influenza vaccine is given with COVID-19 vaccine, a role the Overview does not discuss. They also move the entity into health-economic planning by estimating the value of publicly funded vaccination for older adults. Together, they support use in policy and surveillance frameworks rather than changing the vaccine’s established preventive purpose. 42053343Apr42062199Apr

Overview update candidates: vaccine effectiveness in children/adolescents across real-world outcomes; repeated annual vaccination may alter hospitalization protection; vaccine hesitancy and delivery barriers; safety surveillance in autoimmune/immunocompromised pediatric populations and with COVID-19 coadministration; cost-effectiveness of publicly funded vaccination for older adults.